Sunitinib is a new class of drugs that can selectively target multiple receptor tyrosine kinases, and is now being used alone or in combination with other antitumor drugs to treat many solid tumors, including liver cancer, renal cancer, and gastric cancer (72–74). Here, NTRK1 is linked to renal carcinoma.